Protein Production
293FT, 293E, CHO

Truly Functional Protein
95% Purity
1-10 mg in 2 weeks

GeneExpressoMax™
293Expresso™

Transfection Reagents
* 90% Efficiency
* 95% Viability
* No sera interference
* Simple protocol
* High-throughput
* Only $98/ml

Baculovirus
Functional Protein
95% Purity
Fast turnaround
1-10 mg from Sf9 cells

Adenovirus, AAV
& Lentivirus

ORF or shRNA
* High Titer
* Cre, FLP, ΦC31
* Protein Kinases
* Transcription Factors
* Luciferases, GFP, RFP
* Protein Production
* Stable Cell Line


Excellgen

Jaymie R Meliker
State University New York Stony Brook

Project start date: 2011-04-01

Project end date: 2015-01-31


Sponsored Links Excellgen http://Excellgen.com

Baculovirus Protein Expression
Fast turn around, >95% purity functional protein. No outsourcing to China or India. $5500, $3950
Recombinant Lentivirus & Adenovirus
High Yield and High Titer up to 1010 (lentivirus) and 1013 (adenovirus) for Guaranteed Expression of GOI. $3000, $2500
Transient Protein Expression in CHO and HEK293 Cells
Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. $5500, $3950


Grants awarded to Jaymie R Meliker

Space-Time Clustering Of Non-Hodgkin´s Lymphoma Using Residential Histories

Jaymie R Meliker, Research Scientist
Preventive Medicinestate University New York Stony Brook

Grant 5R03CA125827-02 from National Cancer Institute IRG: ZCA1

Abstract: The primary objective of the proposed research project is to generate valuable insights concerning the etiology of Non-Hodgkin´s lymphoma (NHL) by investigating space-time clustering of current and past residences of cases and controls in a large, multi-center, population-based study in the United States. Despite more than 300,000 cases of NHL diagnosed each year worldwide, accounting for approximately 2.8% of all cancers, relatively little is known about the etiology of NHL. The established and presumptive risk factors, taken as a whole, account for only a small proportion of the total NHL cases that occur annually, and novel techniques are needed to solve this enigma. Our research team has recently developed Q-statistics and Space-Time Information System (STISTM) technology that enable space-time cluster analyses. Other methods for analyzing cancer clusters typically ignore residential mobility, and almost exclusively work with static spatial point distributions of place-of-residence at time of diagnosis or time of death. In addition, few spatial techniques adequately account for known risk factors and covariates. Our approach addresses each of these needs by utilizing the residential history of the participants represented as a life-line, and thus evaluates space-time clustering at any moment in the life-course of the residential histories of the cases relative to the residential histories of the controls. In addition, in place of the widely used (but often inappropriate) null hypothesis of spatial randomness, Q-statistics can incorporate each individual´s probability of being a case based on his/her known risk factors and covariates. This project will apply the innovative Q-statistics and STISTM technology to identify spatial clustering of NHL at any moment in the life-course of the residential histories of the cases relative to the residential histories of the controls. This will, for the first time ever, allow epidemiologists to assess possible geographic and temporal clusters of NHL incidence using current and past residences. The proposed research is a secondary analysis of a large, carefully collected pre-exiting multi-center dataset (1321 cases, 1057 controls), with the intended purpose of generating new hypotheses about potential etiologic factors associated with NHL to be investigated in future studies

Project start date: 2008-07-15

Project end date: 2010-06-30